Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Non-Current Assets readings, the most recent being $207.2 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 7.14% to $207.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $829.5 million, a 9.43% decrease, with the full-year FY2025 number at $209.9 million, down 7.84% from a year prior.
  • Non-Current Assets hit $207.2 million in Q1 2026 for Catalyst Pharmaceuticals, down from $209.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $250.8 million in Q4 2023 to a low of $24.8 million in Q2 2022.
  • Median Non-Current Assets over the past 5 years was $209.9 million (2025), compared with a mean of $178.4 million.
  • Biggest five-year swings in Non-Current Assets: decreased 27.75% in 2022 and later soared 719.88% in 2023.
  • Catalyst Pharmaceuticals' Non-Current Assets stood at $54.8 million in 2022, then soared by 357.44% to $250.8 million in 2023, then fell by 9.16% to $227.8 million in 2024, then decreased by 7.84% to $209.9 million in 2025, then decreased by 1.3% to $207.2 million in 2026.
  • The last three reported values for Non-Current Assets were $207.2 million (Q1 2026), $209.9 million (Q4 2025), and $199.1 million (Q3 2025) per Business Quant data.